Technology
Healthcare Executives Embrace Generative AI to Boost Patient Outcomes
Published
2 years agoon
By
Issued on behalf of Avant Technologies Inc.
VANCOUVER, BC, Dec. 12, 2024 /CNW/ — USA News Group News Commentary – The healthcare industry is in the midst of a significant shift, driven by advancements in artificial intelligence (AI), completely revolutionizing the way patient care is administered, and improving outcomes. AI in healthcare is ushering a new era of personalized patient care, improving diagnoses, drug discovery, predictive health management and many more applications. A recent survey found that 90% of healthcare executives see positive return on investment (ROI) from generative AI (GenAI) investments, signalling AI as a crucial tool for driving long-term growth. Behind the scenes, innovators are developing these tools, with recent updates coming from Avant Technologies, Inc. (OTCQB: AVAI), Roche Holding AG (OTCQX: RHHBY, RHHVF), NVIDIA Corporation (NASDAQ: NVDA), Amazon.com, Inc. (NASDAQ: AMZN), and Tempus AI, Inc. (NASDAQ: TEM).
The article continued: At Fortune’s recent Brainstorm AI conference in San Francisco, several healthcare executives voiced their expectation that the technology will transform the field. According to analysts at MarketsandMarkets Research, the Global AI in Healthcare Market is set to hit US$164.16 billion by 2030, growing at an explosive 49.1% CAGR.
Avant Technologies’ Partner, Ainnova, Signs Pilot Program with Roche to Combat Diabetic Retinopathy
Avant Technologies, Inc. (OTCQB: AVAI), an emerging technology company developing solutions in artificial intelligence in healthcare, recently announced it has entered into a strategic alliance with global biotech giant Roche Holding AG (OTCQX: RHHBY, RHHVF), and leading pre-paid health plan provider Salud 360, to begin a pilot program to combat diabetic retinopathy using cutting-edge technology from Avant’s partner Ainnova Tech, a leading healthcare technology company focused on revolutionizing early disease detection using AI.
Roche, Ainnova, and Salud 360 signed a strategic alliance to improve access to vision screening in patients with uncontrolled diabetes with the hope of decreasing the risks of diabetic retinopathy using Ainnova’s advanced technology and a patient-centered approach.
The pilot program will initially be implemented in Costa Rica where diabetes affects about 10.4% of the adult population. If successful, Avant and Ainnova hope to implement a similar program in the United States, Canada, and Europe through Ai-nova Acquisition Corp. (AAC), the company formed by the partnership between Avant and Ainnova.
“At Roche, we are committed to timely diagnosis of diseases to improve clinical outcomes and thus contribute to the sustainability of the healthcare system,” said, Alvaro Soto, General Manager of Roche Central America, Caribbean, and Venezuela. “By leveraging technology, we seek to improve lives, optimize diagnoses, and ensure that every patient has access to timely and effective treatment. With this model, we not only seek to address the problem of diabetic retinopathy, but also to establish a replicable path for other diseases that require innovative solutions.”
The pilot program will use non-mydriatic fundus cameras and artificial intelligence—developed by Ainnova Tech—to automatically analyze retinal images and identify microscopic changes in the retina. Such changes would be an early indicator of diabetic retinopathy without the need for invasive tests.
By implementing the pilot program in Costa Rica, this strategic alliance can take advantage of the country’s robust healthcare system and its focus on technological innovation. Patients who are members of Salud 360 will be the first to benefit from screenings at affiliated clinics. Those at risk will be referred immediately to ophthalmology specialists, guaranteeing comprehensive and timely care.
The results of this pilot program will be the basis for developing the model beyond borders to benefit communities facing similar challenges in accessing medical care.
“We are proud to be able to put our technology at the service of a project that has the potential to prove itself as a massive impact model in early detection, and which we believe is replicable globally,” said Vinicio Vargas, CEO of Ainnova Tech and member of AAC’s Board of Directors. “Today, we are starting with diabetic retinopathy, but the vision is that we can eventually multiply this same effort for other critical diseases that require innovative solutions.”
According to data from the Costa Rican Institute for Research and Teaching in Nutrition and Health (Inciensa), uncontrolled diabetes is the leading cause of preventable blindness in the country’s adult population. To make matters worse, between 20% and 40% of diabetic patients develop diabetic retinopathy, a silent but devastating condition if not detected and treated in time.
According to the World Health Organization, 80% of cases of blindness due to diabetes are preventable with early and effective interventions. Therefore, early detection is crucial and technological innovation can help make a huge difference.
Prior to the Roche announcement, Avant and Ainnova Tech shared that they are also working on advancing Ainnova’s proprietary low-cost retinal camera, which will be used for fundus photography, and seamlessly packaged together with Ainnova’s Vision AI software platform for commercialization.
CONTINUED… Read this and more news for Avant Technologies Inc. https://usanewsgroup.com/2023/10/26/unlocking-the-trillion-dollar-ai-market-what-investors-need-to-know/
Other recent industry developments and happenings in the market include:
NVIDIA Corporation (NASDAQ: NVDA), the world leader in accelerated computing, recently announced that global pharmaceutical and techbio industry leaders, academic pioneers and AI researchers are adopting the open-source NVIDIA® BioNeMo™ Framework to advance drug discovery and accelerate molecule design.
“The convergence of AI, accelerated computing and expanding datasets offers unprecedented opportunities for the pharmaceutical industry, as evidenced by recent Nobel Prize wins in chemistry,” said Kimberly Powell, vice president of healthcare at NVIDIA. “To help unravel the complexities of biological systems, we’ve introduced the open-source BioNeMo Framework, which will enable researchers worldwide to accelerate the development of life-saving treatments.”
Amazon.com, Inc. (NASDAQ: AMZN), through its subsidiary Amazon Web Services, Inc. (AWS), recently announced that XtalPi, a leading global technology company that combines artificial intelligence (AI) and robotics to drive the discovery of medicine and innovative materials, has selected AWS as its strategic cloud provider. XtalPi uses AI, quantum physics, and robotics to drive innovation in life sciences, chemistry, and new materials. Using AWS, XtalPi helps hundreds of companies, including 16 of the world’s top 20 pharmaceutical companies, expedite drug discovery and development, ensure data security and privacy compliance, and enhance their success rates in developing promising new therapies for patients.
“AWS’s security and scalability allow XtalPi to develop cloud-based platforms that enhance the efficiency of drug research for leading pharmaceutical companies worldwide,” said Deepak Nair, director, Healthcare and Life Sciences at AWS. “AI-driven workflows are poised to transform the rate at which we can move through the drug-discovery process, driving new therapy breakthroughs with lower development costs and faster delivery of lifesaving treatments.”
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, recently announced publication of its study, “Actionable structural variant detection via RNA-NGS and DNA-NGS in patients with advanced non-small cell lung cancer,” in JAMA Network Open.
Tempus studied over 5,500 advanced NSCLC patients and found that using both RNA and DNA sequencing identified significantly more actionable genetic variants than DNA testing alone—boosting detection by over 15%. This dual approach more than doubled the discovery of rare, treatment-relevant changes, suggesting it could help doctors better tailor therapies.
“This large study underscores the importance of using both RNA- and DNA-based comprehensive genomic profiling as a standard of care in advanced NSCLC, and more broadly in solid tumors,” said Halla Nimeiri, MD, Chief Development Officer at Tempus. “By integrating RNA and DNA sequencing, we can detect a wider range of actionable alterations that might otherwise go undetected by DNA testing alone. This combined approach enhances clinicians’ ability to provide more personalized treatment options for patients.”
CONTACT:
USA NEWS GROUP
info@usanewsgroup.com
(604) 265-2873
DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. (“MIQ”). MIQ has been paid a fee for Avant Technologies Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares Avant Technologies Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Avant Technologies Inc. which were purchased as a part of a private placement. MIQ reserves the right to buy and sell, and will buy and sell shares of Avant Technologies Inc. at any time thereafter without any further notice. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material disseminated by MIQ has been approved by the above mentioned company; this is a paid advertisement, and we own shares of the mentioned company that we will sell, and we also reserve the right to buy shares of the company in the open market, or through further private placements and/or investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
View original content:https://www.prnewswire.com/news-releases/healthcare-executives-embrace-generative-ai-to-boost-patient-outcomes-302330485.html
SOURCE USA News Group
You may like
Technology
Increased Domestic Options Pave Way for New SHARx Stormproof Solution
Published
55 minutes agoon
November 19, 2026By
Recent federal import changes are raising questions about prescription access and sourcing options. SHARx CEO Corey Durbin says the company’s new Stormproof program is designed to help employers and members navigate uncertainty through expanded sourcing flexibility, prescription advocacy, and additional healthcare support.
ST. LOUIS, Nov. 19, 2026 /PRNewswire/ — Recent media coverage and evolving federal import requirements have drawn renewed attention to prescription sourcing and continuity of access. The news, changing policies, and shifting implementation deadlines have prompted questions from employers and benefits brokers about their sourcing options. The industry experts at SHARx, a supply-chain and procurement management company, have answers.
“Employers and brokers are right to ask what these developments mean for the people who rely on prescriptions, especially high-priced specialty pharmaceuticals,” said Corey Durbin, Chief Executive Officer and Co-founder of SHARx. “But the problem is getting worse as high-cost drugs (those that cost more than $4,000 per year) spending has doubled what it was in 2017. Our response has been in development for months.”
Stormproof emanated from a full review of all member medications. The increase in domestic sourcing options has made the inception of Stormproof possible and will shield employers and members from sourcing uncertainty.
“Stormproof is built around a full analysis of the domestic options and a determination that the value we bring to members and employers can be even greater than it has been. It gives our organization more ways to help members access the medications they need as sourcing conditions change. In this business, the operating conditions can change like the weather. It’s an atmosphere that has always driven us to be a highly responsive organization,” Durbin said.
Preparing for Changing Requirements
Recent headlines, including a November 11, 2026, CNBC report detailing a federal arrest of a top healthcare company official accused of illegal drug importation through an alternative funding program (AFP), come on the heels of Federal agencies announcing changes affecting customs procedures. First, a U.S. Customs and Border Protection (CBP) rule established new requirements for foreign importers of record, the parties legally responsible for declaring imported goods to CBP, takes effect January 5, 2027. Separately, CBP moved the mandatory implementation date for its Entry Type 13 process, an electronic filing process for certain international mail shipments, from October 22, 2026, to January 20, 2027.
The requirements address different customs processes. Their specific effects on individual prescription pathways may depend on how a shipment is handled and on applicable agency requirements. Durbin said SHARx’s policy and operations teams have been preparing for the changes and evaluating options to help members maintain access to their medications while minimizing potential disruptions.
“Policy changes create uncertainty for all stakeholders, but the need for affordable specialty medication is not going away,” said Paul Pruitt, Chief Growth Officer and Co-founder of SHARx. “Our role is to understand what is changing, help employers and members assess their options, and keep working on ways to support both.”
A Flexible Approach to Prescription Access
Stormproof is designed to support members with affordable options, depending on the member or employer preference, member circumstances, and applicable requirements. Durbin says SHARx is still committed to assisting members, most able to obtain their medications at no cost, regardless of sourcing pathways. Employers can choose from two different financial models – both with significant upside to the employer.
The program also includes additional member support designed to complement prescription assistance. These include AI-enhanced mental health and wellness support, 24/7 virtual primary care, and a very affordable weight-loss option that helps replace a benefit many employers had to cut out because of cost.
“Employees need affordable access but should not have to depend on a single sourcing pathway to help them manage high-cost medications,” Durbin said. “Stormproof gives us a broader framework to assist employers and members as circumstances change, while keeping affordability and access at the center of our plans.”
SHARx has worked with employer-sponsored health plans since 2017 to help address the financial impact of high-cost prescription drugs, while adhering to the highest standards of member access and support. The company says it will continue to monitor policy developments and provide clients with updates as it operationalizes Stormproof.
“Storms are part of this landscape, but too many try and run from the storm instead of through it. Stormproof reflects how we respond: stay prepared, adapt as conditions change, and keep working with employers and members to find the fastest path forward through the storm.” Durbin said.
About SHARx
SHARx is a procurement and supply chain management solution for high-cost prescription drugs. Working alongside employer-sponsored health plans, SHARx helps employers address the financial impact of expensive and specialty medications while providing members with personalized advocacy and access to cost-effective sourcing solutions. Learn more at SHARx.com.
References:
U.S. Customs and Border Protection. (2026, November 6). Heightened requirements for foreign importers of record. Federal Register, 91(214), 69977–70007. govinfo.gov/content/pkg/FR-2026-11-06/html/2026-22735.htmgovinfo.govU.S. Customs and Border Protection. (2026, October 14). International mail Entry Type 13 mandatory implementation date extended to Jan. 20, 2027 [News release]. content.govdelivery.com/accounts/USDHSCBP/bulletins/42f29b6Zamost, S. (2026, November 11). Feds arrest top official of healthcare company, alleging illegal drug importation. CNBC. cnbc.com/2026/11/11/canarx-official-arrested-drug-importation.html
Media inquiries:
Karla Jo Helms
JOTO PR™
727-777-4629
Jotopr.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/increased-domestic-options-pave-way-for-new-sharx-stormproof-solution-302944912.html
SOURCE SHARx
Technology
Common Space Selects Satellogic to Build the First Community-Governed, High-Resolution Humanitarian Satellite
Published
55 minutes agoon
November 19, 2026By
Satellogic has been tapped to design, build, launch, and operate a NewSat Mark V satellite for Common Space’s humanitarian Earth observation mission, with launch targeted for July 2027
ST.LOUIS, Nov. 19, 2026 /PRNewswire-PRWeb/ — Common Space, a nonprofit building an independent, community-governed satellite constellation for the public good, today announced it has selected Satellogic Inc., the infrastructure company for Persistent Global Intelligence (PGI), to deliver Common Space’s first high-resolution Earth observation satellite. Satellogic has been tapped, after a competitive request-for-proposals process, to build a NewSat Mark V satellite and manage launch, ground segment, mission operations, and lifetime support for the mission.
Targeted for launch in July 2027, the satellite aims to create a new model for Earth observation: high-resolution imagery collected specifically for humanitarian and public-interest needs, openly licensed, tasked based on community input, and governed with the people and organizations it serves.
High-resolution satellite imagery has become critical infrastructure for understanding a rapidly changing world. Yet much of the world’s highest-resolution imagery remains expensive, restrictively licensed, or hard to access precisely when and where it matters most, leaving humanitarian responders, human rights investigators, and journalists without the independent visibility and verification they need.
Common Space is pioneering a club-good model that makes high-resolution Earth observation more accessible and financially sustainable. Built around unmet demand quantified in Common Space’s 2026 Impact Report, the model turns satellite imagery into shared infrastructure. A single collection can help humanitarians respond to disasters, researchers track disease, journalists verify events, conservationists monitor environmental threats, and human rights investigators preserve evidence. By sharing the infrastructure, its cost, and its value across a growing community, Common Space can scale sustainably to support organizations serving billions of people worldwide.
“Crises aren’t waiting, and neither are we. Common Space is the kind of tech-for-good vision the world needs right now, shaped by an extraordinary community and made possible by supporters who believed in it early,” said Rhiannan Price, Co-Founder of Common Space. “With Satellogic as our spacecraft partner, we’re moving from vision to orbit and putting high-resolution data into the hands of those who need it most. This isn’t just another satellite. We’re building infrastructure to serve people for years to come.”
Common Space’s growing community includes some of the largest humanitarian, human rights, research, conservation, journalism, and mapping organizations in the world. More than 60 organizations have provided letters of support for the mission, including the World Food Programme, Doctors Without Borders, Global Fishing Watch, Humanitarian OpenStreetMap Team, Save the Children, Direct Relief, and Catholic Relief Services. Private-sector organizations will participate through an equitable, paid membership model that helps sustain the shared infrastructure and expand access for the public good.
“Common Space shares our belief that Persistent Global Intelligence shouldn’t be reserved for a few. Humanitarian responders and journalists are often first on the ground and last to get access, yet they need frequent, high-resolution imagery to see what’s really happening so they can act with confidence,” said Luciano Giesso, Vice President of Space Systems at Satellogic. “This mission puts our vision of democratized access into practice. Our vertically integrated approach lets us move quickly and cost-effectively, so imagery can start reaching the organizations that depend on it in 2027.”
Satellogic was selected after Common Space evaluated providers against its technical requirements, community needs, mission alignment, cost, and path to orbit. The NewSat Mark V will capture 4-band multispectral (RGB and near-infrared) imagery at 70 cm native resolution, with 50 cm SuperResolution, across a 6.5 km swath and up to 350,000 square kilometers of collection capacity per day. On-board edge computing will enable processing in orbit.
The mission builds on Satellogic’s long-standing commitment to humanitarian access. Since 2021, Satellogic has been an approved data contributor to the International Charter Space and Major Disasters, providing high-resolution, high-frequency imagery at no cost to the Charter’s Authorized Users during disaster activations worldwide. Satellogic imagery also supports disaster response through NASA’s Commercial Satellite Data Acquisition (CSDA) program, and the company provides free imagery to researchers through its Research & Science Program.
Satellogic designs, builds, and operates its spacecraft in-house, which allows it to deliver dedicated satellites on fast timelines without the cost and risk of new development. The company has a 100% deployment success rate across more than 60 launched satellites.
This first satellite is just the beginning. Common Space is raising philanthropic capital to build a six-satellite constellation capable of daily high-resolution coverage of priority areas worldwide by 2030, creating reliable infrastructure that organizations can build into everyday preparedness, research, decision-making, and response.
About Common Space
Common Space is a nonprofit building an independent, community-governed humanitarian satellite constellation for open, public-benefit Earth observation. Its high-resolution imagery is openly licensed, tasked by humanitarian need, and governed by and for the people and organizations it serves. Organizations interested in membership, partnership, or funding can learn more at commonspace.world.
About Satellogic
Founded in 2010, Satellogic builds the infrastructure for Persistent Global Intelligence (PGI): continuous, proactive awareness of the places, assets, and activities that matter. The company combines high-cadence satellite collection, best-in-class technology, AI-accelerated workflows, and sovereign-trusted architecture to help customers move from episodic imagery to persistent monitoring programs.
Satellogic serves allied defense and intelligence agencies, civil governments, and commercial markets that need reliable, scalable awareness of change across large portfolios of sites. Customers can begin with discovery, expand into persistent monitoring, and build toward dedicated or sovereign-controlled capacity as their mission requirements grow. To learn more, please visit: https://www.satellogic.com.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the U.S. federal securities laws. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements are based on Satellogic’s current expectations and beliefs concerning, among other things, the capabilities, performance, and potential applications of Satellogic’s satellites, constellations, satellite software, and pipeline. Although we believe our plans, intentions and expectations reflected in or suggested by these forward-looking statements are reasonable, we cannot give any assurance that we either will achieve or realize these plans, intentions or expectations. Forward-looking statements are inherently subject to risks, uncertainties and assumptions, including risks related to the performance of satellites and software once in orbit and reliance on third parties. Many actual events and circumstances are beyond the control of the Company. Many factors could cause actual future results to differ materially from the forward-looking statements in this press release, including but not limited to the risks and uncertainties described in the “Risk Factors” section of Satellogic’s Annual Report on Form 10-K and other documents filed or to be filed by Satellogic from time to time with the Securities and Exchange Commission. Forward-looking statements speak only as of the date they are made. Satellogic assumes no obligation and does not intend to update or revise forward-looking statements, whether as a result of new information, future events, or otherwise.
Contacts
Common Space Media Relations:
Bill Greer, bill@commonspace.world, +1.607.342.2106
Satellogic Media Relations:
Satellogic Investor Relations:
Media Contact
Bill Greer, Common Space, 1 6073422106, bill@commonspace.world, https://www.commonspace.world
Satellogic Media Relations, Satellogic, pr@satellogic.com, https://satellogic.com/
View original content to download multimedia:https://www.prweb.com/releases/common-space-selects-satellogic-to-build-the-first-community-governed-high-resolution-humanitarian-satellite-302945072.html
SOURCE Common Space
Technology
National Australia Bank Modernizes ATM Network with Diebold Nixdorf Cash Recycling ATMs and Payments Platform
Published
55 minutes agoon
November 19, 2026By
Integrated hardware and software solutions will enhance customer experiences, optimize cash management and support new physical and digital journeys for consumers across Australia
NORTH CANTON, Ohio, Nov. 19, 2026 /PRNewswire/ — Diebold Nixdorf (NYSE: DBD) announced that National Australia Bank (NAB) is modernizing customer experiences across its self-service network with more than 700 DN Series® cash recycling ATMs combined with the company’s next-generation Vynamic® Acquiring platform.
Through 2028, NAB will upgrade its ATMs while transforming the software infrastructure that supports physical and digital transactions. Vynamic Acquiring is built on Diebold Nixdorf’s Vynamic Transaction Middleware platform and uses cloud-native, microservices-based architecture. The solution will help NAB modernize its switching environment, support regulatory compliance and introduce new customer journeys.
NAB’s ATMs support more than 500,000 transactions each week, underscoring the continued importance of convenient, dependable cash access alongside digital and in-branch banking. The initiative will:
Improve availability across NAB’s network with modern, highly reliable ATMs, with at least two at most branches.Streamline the cash cycle by securely reusing deposited banknotes for future withdrawals, reducing replenishment needs.Deliver a significantly improved customer experience through clearer screens, faster processing and additional accessibility and language options.Reduce ATM disputes and improve resolution outcomes by increasing visibility into cash transactions, user interactions and deposits and withdrawals.
ATM monitoring, diagnostics, services and maintenance will be provided by ITS, Diebold Nixdorf’s licensed partner in Australia.
Paul Carter, Executive Retail Banking at National Australia Bank at National Australia Bank, said: “Our investment in Diebold Nixdorf’s cash recycling ATMs and payments middleware strengthens our commitment to providing convenient, dependable cash access and the best customer experience in this market for individuals and small businesses across Australia. By automating more cash-handling processes, improving cash availability and reducing operational interventions, we can serve customers more dependably and efficiently wherever and whenever they need access to their money.”
Jaivinder Singh Gill, senior vice president and managing director, Banking and Retail – APMEA at Diebold Nixdorf, said: “NAB’s modernization shows how self-service technology and software can strengthen critical banking infrastructure while creating more connected customer experiences. We are proud to partner with NAB on this nationwide transformation, combining intelligent cash recycling technology, advanced payments software and local expertise to make everyday banking more convenient, secure and reliable.”
About National Australia Bank
At National Australia Bank (NAB) Group, our ambition is to be the most customer-centric company in Australia and New Zealand. More than 41,000 colleagues at the bank provide 10 million customers with secure, easy and reliable banking services. About 88% of the Group’s workforce is located in Australia and New Zealand, while others work in Asia, London, New York and Paris. NAB is proud to be Australia’s largest business lender. We stand by our customers, and they have our ongoing support.
National Australia Bank Limited ABN 12 004 044 937 AFSL and Australian Credit Licence 230686.
About Diebold Nixdorf
Diebold Nixdorf, Incorporated (NYSE: DBD) automates, digitizes and transforms the way people bank and shop. As a leading global technology and services partner to many of the world’s top financial institutions and retailers, our integrated solutions connect digital and physical channels for consumers conveniently, securely and efficiently. The company has a presence in more than 100 countries with approximately 20,000 employees worldwide. Visit www.dieboldnixdorf.com for more information.
X: @DieboldNixdorf
LinkedIn: www.linkedin.com/company/diebold
Facebook: www.facebook.com/DieboldNixdorf
YouTube: www.youtube.com/dieboldnixdorf
DN-B
View original content to download multimedia:https://www.prnewswire.com/news-releases/national-australia-bank-modernizes-atm-network-with-diebold-nixdorf-cash-recycling-atms-and-payments-platform-302944800.html
SOURCE Diebold Nixdorf, Incorporated
Increased Domestic Options Pave Way for New SHARx Stormproof Solution
Common Space Selects Satellogic to Build the First Community-Governed, High-Resolution Humanitarian Satellite
National Australia Bank Modernizes ATM Network with Diebold Nixdorf Cash Recycling ATMs and Payments Platform
Send Rakhi to UK swiftly with UK Gifts Portal
Whiteboard Series with NEAR | Ep: 45 Joel Thorstensson from ceramic.network
Nullmax and Renesas Forge Strategic Partnership to Deliver Competitive ADAS Solutions for the Global Market
Why You Should Build on #NEAR – Co-founder Illia Polosukhin at CV Labs
Whiteboard Series with NEAR | Ep: 45 Joel Thorstensson from ceramic.network
NEAR End of Year Town Hall 2021: The Open Web World, MetaBUILD 2 Hackathon and 2021 recap
Trending
-
Technology5 days agoThe First Cartridge-Free Smart Waterless Diffuser Is Here. What Would You Fill It With?
-
Coin Market4 days agoCoinone warns of phishing, identity theft after customer data breach
-
Near Videos5 days agoBuilders of NEAR: Illia Polosukhin on knowing what your AI agent is running
-
Technology4 days agoIP GUANGDONG debuts at the Media Center of APEC Economic Leaders’ Week
-
Technology5 days agoEFICYENT to Join Banks and Fintech Companies at Singapore FinTech Festival 2026
-
Technology5 days agoHONGQI EHS4 Set for Global Debut in Venice: Eastern Elegance Arrives in Europe
-
Technology4 days agoAPEC 2026 Host City Promotional Video Shenzhen: Where the Future Takes Shape Released Worldwide
-
Technology4 days agoCambodia Takes Bakong Global, Connecting ASEAN with Japan and Africa
